NADH:ubiquinone oxidoreductase subunit B8Genealiases: ASHI · CI-ASHI · MC1DN32
Q-omics provides the consensus-scored NDUFB8 profile across patient tissues and cancer cell-line models. NDUFB8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFB8 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, NDUFB8 protein abundance shows 23,613 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KICH, and GBM as cancer lineages where NDUFB8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFB8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFB8 survival associations across molecular data types. NDUFB8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFB8 RNA expression–survival associations across cancer types. High NDUFB8 expression shows unfavorable associations in UVM, ACC and ESCA, but favorable associations in KIRP, BRCA and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFB8 RNA expression.
This table summarizes NDUFB8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFB8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFB8 shows lower tumor expression in KICH, BLCA, KIRC, READ and HNSC and higher tumor expression in LIHC. The KICH box plot shows higher NDUFB8 RNA expression in normal versus tumor tissue (log2 FC = −0.637, t-test p < 0.001).
This table shows molecular features associated with NDUFB8 in patient tissues and cancer cell lines. In patient samples, NDUFB8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFB8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
